Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05711485 · ClinicalTrials.gov registry record · NA
Platelet-Directed Whole Blood Transfusion Strategy for Malaria
A NA study of Thrombocytopenia and Severe Malaria, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Recruiting
- Registry status
- NA
- Development phase
- 132
- Enrollment target
- 2
- Study locations
NCT05711485: Recruiting NA study of Thrombocytopenia and Severe Malaria, sponsored by Johns Hopkins Bloomberg School of Public Health.
NCT05711485 is a NA study of Thrombocytopenia and Severe Malaria that is actively recruiting participants, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 132 participants, below the 305-participant average among 20 other Thrombocytopenia trials with a reported enrollment target (57% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05711485, a NA study of Thrombocytopenia and Severe Malaria, is actively recruiting participants, sponsored by Johns Hopkins Bloomberg School of Public Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 132 participants
- Enrollment target
- 2
- Study locations
Study Summary
Open-label randomized controlled trial to test the effectiveness of whole blood transfusion for improving survival in children with severe malaria complicated by thrombocytopenia.
Primary Outcome
Death due to any cause
Conditions Studied
Interventions
- OTHER Whole blood transfusion
Study Locations (2)
Maryland
- Johns Hopkins Bloomberg School of Public Health - Baltimore
Copperbelt
- Tropical Diseases Research Centre - Ndola
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2024-02-24 |
| Est. Completion | 2028-05-31 |
| Phase | NA |
What NCT05711485 shows while recruiting
NCT05711485 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 305-participant average among 20 other Thrombocytopenia trials with a reported enrollment target (57% lower).
The record links to 2 conditions, with Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention - of which Whole blood transfusion is the first listed.
NCT05711485 reports a single indexed study location in Maryland, Copperbelt.
Frequently Asked Questions
What is clinical trial NCT05711485 about?
NCT05711485 is a clinical study titled "Platelet-Directed Whole Blood Transfusion Strategy for Malaria". Open-label randomized controlled trial to test the effectiveness of whole blood transfusion for improving survival in children with severe malaria complicated by thrombocytopenia.
What is the current status of trial NCT05711485?
This trial is currently recruiting. It is a NA study. The enrollment target is 132 participants. The study started on 2024-02-24. Estimated completion is 2028-05-31.
What conditions does trial NCT05711485 study?
This clinical trial studies the following conditions: Thrombocytopenia, Severe Malaria.
What interventions are being tested in trial NCT05711485?
The interventions under investigation include: Whole blood transfusion (OTHER).
Who is sponsoring clinical trial NCT05711485?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05711485 being conducted?
This trial has 2 study locations across Maryland, Copperbelt. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05711485's enrollment target sits among peer trials
132 5th of 20 higher than 16 of 20 other Thrombocytopenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thrombocytopenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neonatal Platelet Transfusion Threshold Trial
RECRUITING · NA
-
Optimizing Pulsatility During Cardiopulmonary Bypass to Reduce Acute Kidney Injury
RECRUITING · NA
-
Effects of a Platelet Transfusion Best Practices Alert
COMPLETED · NA
-
Stem Cell Transplantation (SCT) for Genetic Diseases
COMPLETED · NA
-
Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence
COMPLETED · NA
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI